Radioimmunotherapy with α-Particle–Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy
Open Access
- 15 September 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (18) , 5604s-5612s
- https://doi.org/10.1158/1078-0432.ccr-07-1071
Abstract
Purpose: Previous experience in solid tumor radioimmunotherapy studies has indicated that greatest therapeutic efficacy is achieved in the treatment of small-volume disease. α-Particle–emitting radioisotopes possess several physical characteristics ideally suited to the treatment of minimal residual disease. Therefore, we have investigated the efficacy of the α-particle–emitting bismuth-213 (213Bi) radioimmunotherapy using the humanized anti-Lewis Y (Ley) monoclonal antibody humanized 3S193 (hu3S193).Keywords
This publication has 31 references indexed in Scilit:
- Induction and quantification of γ-H2AX foci following low and high LET-irradiationInternational Journal of Radiation Biology, 2006
- Intralesional targeted alpha therapy for metastatic melanomaCancer Biology & Therapy, 2005
- Fractionated Locoregional Low-Dose Radioimmunotherapy Improves Survival in a Mouse Model of Diffuse-Type Gastric Cancer Using a 213Bi-Conjugated Monoclonal AntibodyClinical Cancer Research, 2005
- Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor ActivityClinical Cancer Research, 2005
- High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse AntibodyClinical Cancer Research, 2005
- Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal DiseaseClinical Cancer Research, 2004
- Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193- N -Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and XenograftsClinical Cancer Research, 2004
- Pretargeted α Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N‴-Tetraacetic Acid-BiotinClinical Cancer Research, 2004
- Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin α-conjugateCancer Letters, 2004
- In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigenProstate Cancer and Prostatic Diseases, 2002